Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder

Drugs

Volumn 56, Issue 2, 1998, Pages 215-223

  Cyr, Monica ^a   Brown, Candace S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CLONIDINE; DEXAMPHETAMINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PEMOLINE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; HUMAN; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PSYCHOSOCIAL CARE; SCHOOL; SCHOOL CHILD;

EID: 0031817791     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856020-00005     Document Type: Article

References (64)

1. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994; 78-85
2. World Health Organization. Mental and behavioural disorders. In: International statistical classification of disease and related health problems. Vol. 1. 10th rev. Geneva: World Health Organization, 1992; 378-9
3. Evans RW, Gaultieri CT, Hicks RE. A neuropathic substrate for stimulant drug effects in hyperactive children. Clin Neuropharmacol 1986; 9: 264-81
4. Prendergast M, Taylor E, Rapoport JL, et al. The diagnosis of childhood hyperactivity: a U.S.-U.K. cross-national study of DSM-III and ICD-9. J Child Psychol Psychiatry 1988; 29: 289-300
5. Szatmari P, Offord DR, Boyle MH. Ontario child health study: prevalence of attention deficit disorder with hyperactivity. J Child Psychol Psychiatry 1989; 30: 219-30
6. Baumgaertel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry 1995; 34: 629-38
7. Goodman R, Stevenson J. A twin study of hyperactivity: II. The aetiologic role of genes, family relationships, and perinatal adversity. J Child Psychol Psychiatry 1989; 30: 691-709
8. Cantwell DP. Hyperactive children have grown up: what have we learned about what happens to them? Arch Gen Psychiatry 1985; 42: 1026-8
9. Searight HR, Nahlik JE, Campbell DC. Attention-deficit/hyperactivity disorder: assessment, diagnosis, and management. J Fam Pract 1995; 40: 270-9
10. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1947; 36 (10 Suppl.): 85-121S
11. Richters JW, Arnold LE, Jensen PS, et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. J Am Acad Child Adolesc Psychiatry 1945; 34: 987-1000
12. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409-32
13. Elia J, Borcherding BG, Rapoport JL, et al. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 1991; 36: 141-55
14. Jacobvitz D, Sroufe LA, Stewart M, et al. Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: a comprehensive review. J Am Acad Child Adolesc Psychiatry 1990; 29: 677-88
15. Livingston RL, Dykman RA, Ackerman PT. Psychiatric comorbidity and response to two doses of methylphenidate in children with attention deficit disorder. J Child Adolesc Psychopharmacol 1942; 2: 115-22
16. Aman MF, Marks RE, Turbott SH, et al. Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 1992; 30: 246-56
17. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with ADHD: a comparison of standard methylphenidale, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990; 86: 226-37
18. Fitzpatrick PA, Klorman R, Brumaghim JT, et al. Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 226-34
19. Pelham WE, Swanson JM, Furman MB, et al. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 1995; 34: 1504-13
20. Stevenson RD, Wolraich ML. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Clin Pharmacol 1989; 36: 1183-97
21. Berkovitch M, Pope E, Phillips J, et al. Pemoline-associated fulminant liver failure: testing the evidence for causal ion. Clin Pharmacol Ther 1995; 57: 696-8
22. Bezchlibnyk-Butler KZ, Jeffries JJ, editors. Clinical handbook of psychotropic drugs. Toronto: Hogrefe & Huber, 1996
23. Klein RG, Mannuzza S. Hyperactive boys almost grown up: methylphenidale effects on ultimate height. 1998; 45: 1127-30
24. Spencer TJ, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry 1996; 35: 1460-9
25. Greenhill LL. Stimulant-related growth inhibition in children: a review. In: Gittleman M, editor. Strategic interventions for hyperactive children. New York: ME Sharp, 1981: 39-63
26. Lowe TL, Cohen DJ, Detlor J, et al. Stimulant medications precipitate Tourette's syndrome. JAMA 1982; 247: 1729-31
27. Erenberg G, Cruse RP, Rothner AD, Gilles de la Tourette's syndrome: effects of stimulant drugs. Neurology 195; 35: 1346-8
28. Sverd J, Gadow KD, Paolicelli LM. Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette's syndrome. J Am Acad Child Adolesc Psychiatr 1989; 28: 574-9
29. Knell ER, Comings DE. Tourette's syndrome and attention-deficit hyperactivity disorder: evidence for a genetic relationship. J Clin Psychiatry 1993; 54: 331-7
30. Pliszka SR. Tricyclic antidepressants in the treatment of children with attention deficit disorder. J Amer Acad Child Adolesc Psychiatry 1987; 26: 127-32
31. Kutcher SP, Reiter S, Gardner DM, et al. The pharmacotherapy of anxiety disorders in children and adolescents. Psychiatr Clin North Am 1992; 15: 41-57
32. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part II. J Amer Acad Child Adolesc Psychiatry 1996; 35: 1575-83
33. Riddle MA, Nelson JC, Kleinman CS, et al. Sudden death in children receiving Norpramin®; a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 1991; 30: 104-8
34. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993; 32: 792-7
35. Popper CW, Zimnitzky B. Sudden death putatively related to desipramine treatment in youth: a fifth case and a review of speculative mechanisms. J Child Adolesc Psychopharmacol 1995; 5: 283-300
36. Varley CK, McClellan J. Case study: two additional sudden deaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 1997; 36: 390-4
37. Wilens TE, Biederman J, Baldessarini RJ, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35: 1491-501
38. Priest RG, Gimhrett R, Roberts M, et al. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatrica Scandinavica 1995; 386: 40-3
39. Trott GE, Friese HJ, Menzel M, et al. Use of moclobemide in children with attention deficit hyperactivity disorder. Jugendpsychiat 1991; 19: 248-53
40. Zametkin A, Rapoport JL, Murphy DL, et al. Treatment of hyperactive children with monoamine oxidase inhibitors: I. Clinical efficacy. Arch Gen Psychiatry 1985; 42; 962-6
41. Wender PH, Wood DR, Reimherr F, et al. An open trial of pargyline in the treatment of attention deficit disorder, residual type. Psychiatry Res 1983; 9: 329-36
42. Wood D, Reimherr F, Wender P. The use of 1-deprenyl in the treatment of attention deficit disorder, residual type. Presented at the American College of Neuropsychopharmacology, 1982, San Juan, Puerto Rico
43. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996; 35: 1314-21
44. Clay TH, Gualtieri CT, Evans RW, et al. Clinical and neuropsychological effects of the novel antidepressant bupropion. Psychopharmacol Bull 1988; 24; 143-8
45. Casat CD, Pleasants DZ, Schroeder DH, et al. Bupropion in children with attention deficit disorder. Psychopharmacol Bull 1989; 25: 198-201
46. Casat CD, Pleasants DZ, Van Wyck Fleet J. A double-blind trial of hupropion in children with attention deficit disorder. Psychopharmacol Bull 1987; 23: 120-2
47. Wolfe KD, Weller EB, Weller RA, et al. Treating children with attention-deficit disorder: a double-blind trial. Presented at the 40th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 1993; San Antonio (TX)
48. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 649-57
49. Roose SP, Classman AH, Giardina EGV, et al. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. Am J Psychiatry 1991; 148: 512-6
50. Griffith JD, Griffith C, Carranza J, et al. Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatry 1983; 44: 206-8
51. Jacobsen LK, Chappell P, Woolston JL. Bupropion and compulsive behavior. J Am Acad Child Adolesc Psychiatry 1994; 33: 143-4
52. Spencer T, Biederman J, Steingard R, et al. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993; 32: 211-4
53. Barrickman L, Nayes R, Kuperman S, et al. Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 1991; 305: 762-7
54. Campbell NB, Tamburrino MB, Evans CL, et al. Fluoxetine for ADHD in a young child. J Am Acad Child Adolesc Psychiatry 1995; 34: 1259-60
55. Frankenburg FOR, Kando JC. Sertraline treatment of attention deficit hyperactivity disorder and Tourette's syndrome. J Clin Psychopharmacol 1994; 14: 359-60
56. Gunning B. A controlled trial of clonidine in hyperkinetic children [thesis]. Department of Child and Adolescent Psychiatry. Academic Hospital Rotterdam, Sophia Children's Hospital Rotterdam, 1992
57. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial J Am Acad Child Psychiatry 1985; 24: 617-29
58. Hunt Rd, Minderaa RB, Cohen DJ. Therapeutic effect of clonidine in attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate. Psychopharmacol Bull 1986; 22: 229-36
59. Cantwell DP, Swanson J, Connor DF. Case study: adverse response to clonidine. J Am Acad Child Psychiatry 1997; 36: 539-44
60. Edlebrock CS, Rancurello MD. Childhood hyperactivity: an overview of rating scales and their applications. Clin Psychol Rev 1985; 5: 429-45
61. Conners CK. A teacher rating scale for use in drug studies with children. Am J Psychiatry 1969; 126; 884-8
62. Achenbach TM. Integrative guide for the 1991 CBCL/4-18, YSR, and TRF profiles. Burlington: University of Vermont Department of Psychiatry, 1991
63. Barkley RA. Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment. New York: Guillord, 1990
64. Achenbach TM. Manual for the Teacher's Report Form and 1991 Profile. Burlington: University of Vermont Department of Psychiatry, 1991